中文
Earlier issues
Announcement
More
Progress in Chemistry 2013, Vol. 25 Issue (09): 1517-1525 DOI: 10.7536/PC130721 Previous Articles   Next Articles

Driver Genes as Targets for Lung Cancer Prevention and Treatment

Donghai Xiong1, Raymond U. Osarogiagbon2, Yian Wang3, Ming You*1,3   

  1. 1. Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA;
    2. Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, 80 Humphries Center Drive, Memphis, TN 38120, USA;
    3. Department of Surgery and The Alvin J Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
  • Received: Online: Published:
Richhtml ( 0 ) PDF ( 1359 ) Cited
Export

EndNote

Ris

BibTeX

Next generation sequencing (NGS) has been widely used in identifying the most important driver genes to lung carcinogenesis. Compared to the traditional sequencing approaches such as Sanger sequencing, NGS has several distinct advantages including the capacity to fully sequence almost all of the genes in the whole genome, whole exome or whole transcriptome, and the ability to simultaneously detect all types of genetic variants such as base substitutions (mutations), insertions, deletions, copy number variants, structural variants, gene fusions, etc. In the past few years, several comprehensive NGS studies on three major types of lung cancer (lung adenocarcinoma, squamous cell lung cancer, and small-cell lung cancer) have been successfully conducted which both confirmed the significance of the previously identified lung cancer driver genes and revealed the ‘novel’ significant driver genes that were not well known in the lung cancer context before. Functional somatic genetic alterations in these genes exist in the majority of the lung cancer samples studied and altered the critical pathways whose aberrations have a direct impact on lung cancer development. It is anticipated that the expanding list of lung cancer driver genes will provide unprecedented opportunities to identify the best targets for lung cancer prevention and treatment.

Key words: next generation sequencing (NGS), driver gene, lung cancer, prevention

CLC Number: 

[1] Imielinski M, Berger A H, Hammerman P S, et al. Cell, 2012, 150: 1107—1120
[2] Govindan R, Ding L, Griffith M, et al. Cell, 2012, 150: 1121— 1134
[3] Hodis E, Watson I R, Kryukov G V, et al. Cell, 2012, 150: 251— 263
[4] Hammerman P S, Hayes D N, Wilkerson M D, et al. Nature, 2012, 489: 519—525
[5] Ekstrand A J, Sugawa N, James C D, Collins V P. Proc. Natl. Acad. Sci. U. S. A., 1992, 89: 4309—4313
[6] Cho J, Pastorino S, Zeng Q. et al. Cancer Res., 2011, 71: 7587— 7596
[7] Pines G, Huang P H, Zwang Y. et al. Oncogene, 2010, 29: 5850— 5860
[8] Dees N D, Zhang Q, Kandoth C, et al. Genome Res., 2012, 22: 1589—1598
[9] Watanabe A, Ogiwara H, Ehata S, et al. Proc. Natl. Acad. Sci. U. S. A., 2011, 108: 12384—12389
[10] Wu K, Katiyar S, Witkiewicz A, et al. Cancer Res., 2009, 69:3347—3355
[11] Zhang J, Ding L, Holmfeldt L, et al. Nature, 2012, 481: 157—163
[12] Peifer M, Fernandez-Cuesta L, Sos M L, et al. Nat. Genet., 2012, 44: 1104—1110
[13] Rudin C M, Durinck S, Stawiski E W, et al. Nat. Genet., 2012, 44: 1111—1116
[14] Kan Z, Jaiswal B S, Stinson J, et al. Nature, 2010, 466: 869—873
[15] Takahashi K, Yamanaka S. Cell, 2006, 126: 663—676
[16] Tompkins D H, Besnard V, Lange A W, et al. PLoS One, 2009, 4: e8248
[17] Lu Y, Futtner C, Rock J R, et al. PLoS One, 2010, 5: e11022
[18] Dutt A, Ramos A H, Hammerman P S, et al. PLoS One, 2011, 6: e20351
[19] Voortman J, Lee J H, Killian J K, et al. Proc. Natl. Acad. Sci. U. S. A., 2010, 107: 13040—13045
[20] Weiss J, Sos M L, Seidel D, et al. Sci. Transl. Med., 2010, 2: 62ra93
[21] Taguchi A, Politi K, Pitteri S J, et al. Cancer Cell, 2011, 20: 289—299
[22] Tseng R C, Lee S H, Hsu H S, et al. Cancer Res., 2010, 70: 543— 551
[23] Xian J, Clark K J, Fordham R, et al. Proc. Natl. Acad. Sci. U. S. A., 2001, 98: 15062—15066
[24] Holmberg J, Clarke D L, Frisen J. Nature, 2000, 408: 203—206
[25] Druker B J, Tamura S, Buchdunger E, et al. Nat. Med., 1996, 2: 561—566
[26] Druker B J, Talpaz M, Resta D J, et al. N. Engl. J. Med., 2001, 344: 1031—1037
[27] Gorre M E, Mohammed M, Ellwood K, et al. Science, 2001, 5531: 876—880
[28] Roumiantsev S, Shah N P, Gorre M E, et al. Proc. Natl. Acad. Sci. U. S. A., 2002, 99: 10700—10705
[29] Shah N P, Sawyers C L. Oncogene, 2003, 22: 7389—7395
[30] Talpaz M, Shah N P, Kantarjian H, et al. N. Engl. J. Med., 2006, 354: 2531—2541
[31] Kantarjian H, Giles F, Wunderle L, et al. N. Engl. J. Med., 2006, 354: 2542—2551
[32] Thatcher N, Chang A, Praikh P, et al. Lancet, 2005, 366: 1527— 1537
[33] Lynch T J, Bell D W, Sordella R, et al. N. Engl. J. Med., 2004, 350: 2129—2139
[34] Paez J G, Janne P A, Lee J C, et al. Science, 2004, 304: 1497— 1500
[35] Pao W, Miller V, Zakowski M, et al. Proc. Natl. Acad. Sci. U. S. A., 2004, 101: 13306—13311
[36] Mok T S, Wu Y, Thongprasert S, et al. N. Engl. J. Med., 2009, 361: 947—957
[37] Maemondo M, Inoue A, Kobayashi K, et al. N. Engl. J. Med., 2010, 362: 2380—2388
[38] Rosell R, Carcereny E, Gervais R, et al. Lancet Oncol., 2012, 13: 239—246
[39] Sharma S, Bell D W, Settleman J, Haber D A. Nat. Rev. Cancer, 2007, 7: 169—181
[40] Rosell R, Moran T, Queralt C, et al. N. Engl. J. Med., 2009, 361: 958—967
[41] Kobayashi S, Boggon T J, Dayaram T, et al. N. Engl. J. Med., 2005, 352: 786—792
[42] Pao W, Miller V A, Politi K A, et al. PLoS Med., 2005, 2: 0225— 0235
[43] Kwak E L, Sordella R, Bell D W, et al. Proc. Natl. Acad. Sci. U. S. A., 2005, 102: 7665—7670
[44] Yang J C, Shih J, Su W, et al. Lancet Oncol., 2012, 13: 539—548
[45] Nakagawa T, Takeuchi S, Yamada T, et al. Mol. Cancer Ther., 2012, 11: 2149—2157
[46] Soda M, Choi Y L, Enomoto M, et al. Nature, 2007, 448: 561— 566
[47] Morris S W, Kirstein M N, Valentine M B, et al. Science, 1994, 263: 1281—1284. Erratum: Science, 1995, 267: 316—317
[48] Kwak E L, Bang Y, Camidge D R, et al. N. Engl. J. Med., 2010, 363: 1693—1703
[49] Dai Z, Kelly J C, Meloni-Ehrig A, et al. Mol. Cytogenet., 2012, 5: 44
[50] Choi Y L, Soda M, Yamashita Y, et al. N. Engl. J. Med., 2010, 363: 1734—1739
[51] Pao W, Girard N. Lancet Oncol., 2011, 12: 175—180
[52] Oxnard G R, Binder A, Janne P A. J. Clin. Oncol., 2013, 31(8): 1097—1104
[53] Bergethon K, Shaw A T, Ou S I, et al. J. Clin. Oncol., 2012, 30: 863—870
[54] Shaw A T, Camidge D R, Engelman J A, et al. J. Clin. Oncol., 2012, 30: 482S (suppl; abstr 7508)
[1] Zeng Hongmei, Chen Wanqing. Cancer Epidemiology and Control in China：State of the Art [J]. Progress in Chemistry, 2013, 25(09): 1415-1420.
[2] Michael B. Sporn, Karen T. Liby. A Mini-Review of Chemoprevention of Cancer——Past, Present, and Future [J]. Progress in Chemistry, 2013, 25(09): 1421-1428.
[3] Barbara K. Dunn. Phase 3 Trials in Breast Cancer Prevention：Focus on Estrogen-Targeting Agents, Selective Estrogen Receptor Modulators and Aromatase Inhibitors [J]. Progress in Chemistry, 2013, 25(09): 1429-1449.
[4] Andrew T. Chan. Aspirin for the Prevention of Colorectal Cancer [J]. Progress in Chemistry, 2013, 25(09): 1450-1453.
[5] Patricia A. Egner, Jin-Bing Wang, Yuan-Rong Zhu, Lisa P. Jacobson, Derek Ng, Alvaro Muñoz, Jed W. Fahey, Jian-Guo Chen, Tao-Yang Chen, Geng-Sun Qian, John D. Groopman, Thomas W. Kensler*. Prevention of Liver Cancer in Qidong, China：Lessons from Aflatoxin Biomarker Studies [J]. Progress in Chemistry, 2013, 25(09): 1454-1461.
[6] Li Junyao. Nutritional Intervention of Cancer [J]. Progress in Chemistry, 2013, 25(09): 1462-1479.
[7] Gary D. Stoner. Whole Food Approach to Cancer Prevention：Berries as an Example [J]. Progress in Chemistry, 2013, 25(09): 1480-1491.
[8] Chung S. Yang. Cancer Prevention by Vitamin E and Tea Polyphenols：Lessons Learned from Studies in Animal Models and Humans [J]. Progress in Chemistry, 2013, 25(09): 1492-1500.
[9] Zheng-Yuan Su, Limin Shu, Jong Hun Lee, Franciso Fuentes, Hu Wang, Tien-Yuan Wu, Siwang Yu, Ah-Ng Tony Kong. Perspective on Nrf2, Epigenomics and Cancer Stem Cells in Cancer Chemoprevention Using Dietary Phytochemicals and Traditional Chinese Medicines [J]. Progress in Chemistry, 2013, 25(09): 1526-1543.
[10] Wang Xiu Jun*, Li Xin, Tang Xiuwen. The Role of Nrf2 in Carcinogenesis [J]. Progress in Chemistry, 2013, 25(09): 1544-1552.
[11] Song Gao, Sumit Basu, Guangyi Yang, Arijita Deb, Ming Hu. Oral Bioavailability Challenges of Natural Products Used in Cancer Chemoprevention [J]. Progress in Chemistry, 2013, 25(09): 1553-1574.
[12] Weicheng You*, Lian Zhang, Kaifeng Pan, Junling Ma. Anti-Helicobacter pylori Infection in Gastric Cancer Prevention [J]. Progress in Chemistry, 2013, 25(09): 1575-1582.
[13] Wang Shaoming, Qiao Youlin. Vaccine and Cancer Prevention [J]. Progress in Chemistry, 2013, 25(09): 1583-1587.
[14] Tao Niu, Ming Hu. Microbiota Structures, Human Health and Cancer Chemoprevention [J]. Progress in Chemistry, 2013, 25(09): 1601-1612.
[15] Chen Wenming. Cleaner Production ——A New Realization of Environmental Strategy [J]. Progress in Chemistry, 1998, 10(02): 113-.